Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. - Wikidata - wikimedia - TriplyDB

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

http://www.wikidata.org/entity/Q35000581

about

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Current status of allogeneic hematopoietic cell transplantation for MDS.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Current status of allogeneic HST for chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.Stem cell transplant for juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.A Rare Monocytic Crisis of Chronic Myelogenous Leukemia Presenting with Unusual Extramedullary Manifestations and an Atypical (14;22)(q24;q11.2) Translocation in the Bone Marrow.Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.

P2860

Q30274942-59D75434-02DA-454B-8A8B-88E5A86D9A12 Q33600822-C59D911C-1B95-4841-85EC-3CA6B7E3EEF9 Q35608022-2A3525D5-32ED-4C97-A9CB-39E261EB6754 Q35714782-A4A3C240-B70F-43B5-AA07-1D3B9DB62FCB Q35854094-26638926-AB34-4C8F-91A0-074EF222811C Q36063049-EE964D53-DAB5-4D51-9EE8-9C7A1FDA8576 Q36708989-E4779D15-8FB7-4EFC-91A2-88CADB5E7DD6 Q36811828-1CEC6340-EA4B-44CF-A7C2-ED3F2556A816 Q36876853-3884A25D-C7BC-4BD6-8079-BA74BC3DB536 Q36967029-33FBF7F0-5B6C-40C5-A0ED-D5C92CFC32C4 Q37349392-21A714A1-61AF-4A63-A6D3-1ED867EE98B9 Q37899751-2C690323-5699-4D59-9F2F-312DD6163D8C Q38012085-0BCB460A-27EB-4721-AF30-AA06937D5257 Q38130476-B3367D26-9D8B-4AB8-A86F-57FC8F8F718C Q38134374-6DD10DDF-A7E7-4417-9A89-48FF0EF2881E Q38236642-793B81E9-6988-4D0C-912A-6E1975B26567 Q38241774-7B43E0AF-9F1F-4DA3-9E36-188B081D9499 Q38246598-E4A18A95-3AA2-4B3C-ADF3-873109122277 Q38510097-69D304AA-B2F5-4726-87DA-71474CF4BA5B Q38540013-D2C7F08B-EAF9-4115-8641-1585A9D5E0A1 Q38602492-699B3837-22FD-49F6-9208-9B20F0037282 Q38603384-47D73917-2F8D-4678-9D61-61ACA07E011F Q38644826-6E167ECC-D362-4E78-AB3A-7E3FC041EFC9 Q38712988-B6BBBE1A-9FCB-4C36-ADD7-EB0C933CC4F7 Q38835771-3D3AFBD7-D04C-4085-915F-4741A879778E Q38859646-6C94DB86-5AEA-4697-AAE7-4883D47F0B12 Q41652572-37F9F8CB-AF14-4191-A3AF-5BD9574BED7E Q41833461-0B2455D9-8C42-4042-8006-75B2417EFCA7 Q46373480-97C7C7CF-6714-468B-86BF-8148C8797D25 Q47793309-B30FF351-7279-46CB-AD23-E00BC1B5CA7F Q50095934-17610ED9-3CB2-41D0-8A44-2657A415EBF6 Q52846378-6B5D2A3D-4DE1-4F9D-80F2-22CBF5017EE2 Q54979651-7DA6F6A6-20E9-433B-91CA-C3888EA08C79

P2860

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

http://www.wikidata.org/entity/Q35000581

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@ast

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@en

type

label

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@ast

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@en

prefLabel

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@ast

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@en

P1433

Q35000581-82E5959F-96DF-499F-8001-CAABAC8A70DC

P1476

Q35000581-C61BD17B-AD15-4326-A3EF-94F5B50DBA03

P2093

Q35000581-0AF25D0B-6790-46A0-8339-46C0B7710CB2

Q35000581-12486125-361D-48E7-98BB-6565A8F9C8B3

Q35000581-1D90B44E-A96D-4406-A37C-3497CAAC61F7

Q35000581-298FF31F-5C12-4105-9E51-F79DD1A1C333

Q35000581-4058E48F-027C-4011-BA3A-D8AB03E7D1CD

Q35000581-5EB85321-1F78-4183-A2EC-E92E20F11264

Q35000581-9F70F34A-6274-437B-B650-6E36BA3C43A9

Q35000581-A0929202-E541-4E92-A99B-7FEB0F363E00

Q35000581-A4D81583-6B25-4A56-B20A-D65455D90362

Q35000581-CA8A99CD-4E80-447D-8CC0-937DAC20302E

P2860

Q35000581-0F04EDE0-D662-41D3-8636-806F7A0407E2

Q35000581-26F552D5-DB26-4C67-918F-A6FCD49C0507

Q35000581-3F2780A0-CEB5-468A-84D4-1A88C5C90210

Q35000581-4648BFAA-10AE-4CEF-B05E-0C9963C355D8

Q35000581-4CFD527D-9773-4116-8C42-8A490746DFF2

Q35000581-4D44A151-4995-40EB-B738-EFD98F584B73

Q35000581-517406BE-6C7B-4BA6-B3AC-59EA71057B54

Q35000581-5CF68B35-8CB4-44EE-AA44-540627ED2589

Q35000581-5F7D049A-59B8-431C-BF58-F4A241F958EC

Q35000581-65AE97DE-E4D1-47FF-8FDD-B7D41DC4247A

P304

Q35000581-C4DFC14B-1326-45A2-A7B7-8A24AE53A7E8

P31

Q35000581-3A0BA90F-61C6-4DB2-9E3F-780E50DF20F2

P356

Q35000581-20AB117E-E0DE-4B69-BE23-E79895E2A3D1

P433

Q35000581-EB2E3309-C466-4CAA-AAA7-46B731EE3484

P478

Q35000581-23826D93-98C9-4B4A-B4D7-5B5DA130AE2F

P50

Q35000581-23DBE060-D4E2-4967-983D-570D92AFF21A

Q35000581-39489836-1954-41D3-B6A5-9EAD73EA95F3

Q35000581-82CDF7AA-91D9-4297-9B6B-913647B84B1D

Q35000581-9F2B4902-FBA2-4C01-B597-F3DEE8DDB89A

P577

Q35000581-4262AEFF-80B3-40CE-8D28-89906D8B3C2F

P5875

Q35000581-0F1B302E-AE0D-42D2-B3D0-DF3876AFA113

P698

Q35000581-15E91E5D-FC5C-4E24-92EF-F882343E0FE9

P921

Q35000581-48B2A1DA-434B-4797-A8F8-599E18F44675

Q35000581-C457DE63-D80C-45DC-9078-19346B9CF686

P932

Q35000581-2CFCF17A-C5A6-4986-B28B-8E01E0609A3C

P356

J.BBMT.2010.09.018

P1433

Biology of Blood and Marrow Transplantation

P1476

Allogeneic hematopoietic cell ...... y karyotype and comorbidities.

@en

P2093

Bart L Scott

http://www.w3.org/2001/XMLSchema#string

E Houston Warren

http://www.w3.org/2001/XMLSchema#string

Franchesca Nguyen

http://www.w3.org/2001/XMLSchema#string

Hesham Eissa

http://www.w3.org/2001/XMLSchema#string

Jerry P Radich

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Keith R Loeb

http://www.w3.org/2001/XMLSchema#string

Kristine Doney

http://www.w3.org/2001/XMLSchema#string

Mohamed L Sorror

http://www.w3.org/2001/XMLSchema#string

Paul J Martin

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

International scoring system for evaluating prognosis in myelodysplastic syndromes

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

P304

908-915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2010.09.018

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Rainer F. Storb

Brenda M Sandmaier

Frederick R. Appelbaum

Hans Joachim Deeg

P577

2010-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47382145

http://www.w3.org/2001/XMLSchema#string

P698

20932924

http://www.w3.org/2001/XMLSchema#string

P921

P932

3100432

http://www.w3.org/2001/XMLSchema#string